• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

卡培他滨化疗相关的手足红斑性感觉异常：一例报告

Palmar-plantar erythrodysesthesia associated with capecitabine chemotherapy: a case report.

作者信息

Kigen Gabriel, Busakhala Naftali, Njiru Evangeline, Chite Fredrick, Loehrer Patrick

机构信息

Department of Pharmacology &Toxicology, Moi University School of Medicine, Eldoret, Kenya ; Department of Haematology and Oncology, Moi University School of Medicine, Eldoret, Kenya.

Department of Haematology and Oncology, Moi University School of Medicine, Eldoret, Kenya ; Department of Medicine, Moi University School of Medicine, Eldoret, Kenya.

出版信息

Pan Afr Med J. 2015 Jul 30;21:228. doi: 10.11604/pamj.2015.21.228.7525. eCollection 2015.

DOI:10.11604/pamj.2015.21.228.7525
PMID:26523170
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4607982/
Abstract

We report a case of a 62 year-old patient who developed Palmar-plantar erythrodysesthesia upon receiving four cycles of capacitabine-based chemotherapy. She was on post surgical adjuvant treatment for invasive well differentiated adenocarcinoma of the colon. The clinical and therapeutic aspects of this chemotherapeutic adverse effect are discussed.

摘要

我们报告一例62岁患者，在接受四个周期的卡培他滨化疗后出现手足红斑性感觉异常。她正在接受结肠癌术后辅助治疗，病理类型为浸润性高分化腺癌。本文讨论了这种化疗不良反应的临床及治疗相关情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07d8/4607982/3213bd30f91f/PAMJ-21-228-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07d8/4607982/689dec008b16/PAMJ-21-228-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07d8/4607982/1de4d39d87a1/PAMJ-21-228-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07d8/4607982/2b7c65ae819f/PAMJ-21-228-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07d8/4607982/ea59869dd656/PAMJ-21-228-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07d8/4607982/3213bd30f91f/PAMJ-21-228-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07d8/4607982/689dec008b16/PAMJ-21-228-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07d8/4607982/1de4d39d87a1/PAMJ-21-228-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07d8/4607982/2b7c65ae819f/PAMJ-21-228-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07d8/4607982/ea59869dd656/PAMJ-21-228-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07d8/4607982/3213bd30f91f/PAMJ-21-228-g005.jpg

相似文献

1
Palmar-plantar erythrodysesthesia associated with capecitabine chemotherapy: a case report.卡培他滨化疗相关的手足红斑性感觉异常：一例报告
Pan Afr Med J. 2015 Jul 30;21:228. doi: 10.11604/pamj.2015.21.228.7525. eCollection 2015.
2
Unusual scrotal and penile ulcerations together with palmar-plantar erythrodysesthesia syndrome in a patient with metastatic colon carcinoma treated with capecitabine.一名接受卡培他滨治疗的转移性结肠癌患者出现阴囊和阴茎异常溃疡以及手足红斑感觉异常综合征。
J Eur Acad Dermatol Venereol. 2017 Jun;31(6):e304-e306. doi: 10.1111/jdv.14090. Epub 2017 Jan 30.
3
Capecitabine safety profile, innovative and generic adjuvant formulation of nonmetastatic colorectal cancer.卡培他滨的安全性概况、非转移性结直肠癌的创新型和仿制药辅助制剂。
Farm Hosp. 2019 Sep 1;43(5):158-162. doi: 10.7399/fh.11161.
4
Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.JFMC37 - 0801试验的预先计划的安全性分析：一项关于卡培他滨6个月与12个月作为III期结肠癌辅助化疗的随机III期研究。
Int J Clin Oncol. 2017 Jun;22(3):494-504. doi: 10.1007/s10147-016-1083-9. Epub 2017 Jan 11.
5
Unilateral Capecitabine-related Hand-foot Syndrome.单侧卡培他滨相关性手足综合征
Intern Med. 2015;54(21):2779. doi: 10.2169/internalmedicine.54.4920. Epub 2015 Nov 1.
6
A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).一项关于局部应用吡哆醇对卡培他滨或聚乙二醇脂质体阿霉素（PLD）引起的手掌-足底红斑感觉异常（PPE）影响的随机双盲、安慰剂对照的初步研究。
Eur J Oncol Nurs. 2021 Feb;50:101866. doi: 10.1016/j.ejon.2020.101866. Epub 2020 Nov 11.
7
Capecitabine and Hand-foot Syndrome: A Case Report.卡培他滨与手足综合征：一例报告
Infect Disord Drug Targets. 2023;23(1):e140622205973. doi: 10.2174/1871526522666220614162117.
8
"Hand-foot" syndrome-an unusual case of plantar pathology presenting to a burns unit.“手足”综合征——一例出现在烧伤科的罕见足底病变病例。
J Burn Care Res. 2009 May-Jun;30(3):529-32. doi: 10.1097/BCR.0b013e3181a28dc0.
9
A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient.卡培他滨致胃肠道癌症患者手掌色素减退 1 例。
J Oncol Pharm Pract. 2022 Jan;28(1):247-249. doi: 10.1177/10781552211027936. Epub 2021 Jul 7.
10
The concurrence of subacute cutaneous lupus erythematosus and hand-foot syndrome in a patient undergoing capecitabine chemotherapy.一名接受卡培他滨化疗的患者出现亚急性皮肤型红斑狼疮和手足综合征并存的情况。
Australas J Dermatol. 2016 Feb;57(1):e14-6. doi: 10.1111/ajd.12224. Epub 2014 Dec 13.

引用本文的文献

1
Hand-Foot Syndrome Presentation Post-Capecitabine Treatment in a Black Patient.一名黑人患者接受卡培他滨治疗后的手足综合征表现
Cureus. 2022 Jul 15;14(7):e26891. doi: 10.7759/cureus.26891. eCollection 2022 Jul.

本文引用的文献

1
Anticancer drug induced palmar plantar erythrodysesthesia.抗癌药物诱发的手足红斑性感觉异常。
J Clin Diagn Res. 2014 Oct;8(10):HC01-3. doi: 10.7860/JCDR/2014/9133.4975. Epub 2014 Oct 20.
2
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.胞嘧啶脱氨酶启动子的多态性可预测卡培他滨引起的严重手足综合征。
Clin Cancer Res. 2011 Apr 1;17(7):2006-13. doi: 10.1158/1078-0432.CCR-10-1741. Epub 2011 Feb 16.
3
Capecitabine and hand-foot syndrome.卡培他滨与手足综合征。
Expert Opin Drug Saf. 2011 Mar;10(2):159-69. doi: 10.1517/14740338.2011.546342. Epub 2010 Dec 22.
4
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.COX-2 抑制剂对Ⅱ/Ⅲ期结直肠癌患者卡培他滨所致手足综合征的影响：一项Ⅱ期随机前瞻性研究。
J Cancer Res Clin Oncol. 2011 Jun;137(6):953-7. doi: 10.1007/s00432-010-0958-9. Epub 2010 Nov 27.
5
Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.卡培他滨作为辅助化疗用于结直肠癌患者时手足综合征的依从性和有效管理。
Yonsei Med J. 2009 Dec 31;50(6):796-802. doi: 10.3349/ymj.2009.50.6.796. Epub 2009 Dec 18.
6
Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?5-氟尿嘧啶和卡培他滨在一名TYMS基因多态性患者中的毒性与疗效：挑战还是困境？
Clin Colorectal Cancer. 2009 Oct;8(4):231-4. doi: 10.3816/CCC.2009.n.039.
7
Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity?一名接受卡培他滨治疗且二氢嘧啶脱氢酶（DPD）活性正常的非裔美国患者出现非典型手足综合征：是否存在种族差异？
Cutan Ocul Toxicol. 2008;27(4):311-5. doi: 10.1080/15569520802355774.
8
Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.手足红斑性感觉异常（PPE）：一项文献综述及对癌症中心经验的评论
Eur J Oncol Nurs. 2007 Jul;11(3):238-46. doi: 10.1016/j.ejon.2006.10.004. Epub 2007 Mar 9.
9
Management of hand-foot syndrome induced by capecitabine.卡培他滨所致手足综合征的管理
J Oncol Pharm Pract. 2006 Sep;12(3):131-41. doi: 10.1177/1078155206069242.
10
Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.认识手足综合征。评估卡培他滨的临床试验见解。
Oncology (Williston Park). 2004 Aug;18(9):1161-8, 1173; discussion 1173-6, 1181-4.